Affiliations/addresses:
Introduction
Haemophilia and von Willebrand disease (VWD) due to deficiency of FVIII/IX and von Willebrand factor (VWF) respectively, comprise the most common inherited bleeding disorders. Despite the obvious differences in mode of inheritance and pathophysiology, they share a number of characteristics. As with all the inherited bleeding disorders, there is a direct relationship between the severity of the factor deficiency and the symptoms of disease and correction of the deficiency stops and prevents bleeding.
VWD is caused by abnormalities in the VWF gene on chromosome 12, with an autosomal dominant or recessive inheritance pattern (1) . Although VWD is the most common inherited bleeding disorder, most diagnosed individuals have mild disease (2) . Typical symptoms are those of mucosal bleeding including epistaxis, menorrhagia, as well as skin bruising and bleeding after surgery and dental extractions. Treatment of VWD is primarily conducted with tranexamic acid, desmopressin or VWF/FVIII concentrate, which are given to stop bleeding or prevent bleeding in the context of surgery. In contrast to the situation in haemophilia, the use of long-term prophylaxis is less well developed in VWD.
Haemophilia is inherited in a sex-linked manner and largely affects males, although some female carriers can have reduced levels and also be symptomatic.
Typical symptoms are joint and muscle bleeding as well as internal bleeding, and bleeding after surgery and invasive procedures. There is an inverse relationship between residual factor level and severity of bleeding. Individuals with severe (<1% FVIII/IX) disease experience frequent spontaneous joint bleeds and develop arthropathy whilst persons with moderate (1% to <5% FVIII/IX) disease experience joint bleeds less frequently and rarely develop severe arthropathy (5) (6) . This observation led to the suggestion that if you could administer regular FVIII/IX to always have a level above 1% then it should be possible to reduce the number of joint bleeds and convert the phenotype of patients with severe disease to that of moderate/mild individuals.
Haemophilia and prophylaxis
A five-decade clinical experience, starting in Sweden (3-4) has established prophylaxis using regular infusions of factor concentrate as the treatment of choice in children with severe haemophilia.
Data supporting the benefits of prophylaxis in haemophilic patients largely come from retrospective or non-controlled studies. The different cohorts of patients described in the Malmo experience (3) and in other studies in the following years (7-9) evaluated short-term outcome such as frequency of joint bleeds, or long-term clinical outcome such as arthropathy (10) (11) . Clinical and radiological scores demonstrated that signs of arthropathy were not detectable in children starting prophylaxis before two years of age (8) , or showing that only younger children receiving higher doses earlier in life did not develop any bleeding episode (3) . In some of these st Q Life (QoL) were also investigated (e.g., number of hospital visits and hospitalisations, number of school/work days lost).
Despite the long clinical experience and extensive use of prophylaxis in this setting, a Cochrane review in 2006 concluded that evidence supporting clinical benefits of prophylaxis over on-demand therapy was insufficient (12) . In the last decade, however, several randomized-controlled studies (13-14) have definitively confirmed primary prophylaxis as the gold standard of care in severe hemophilia, and national guidelines in several countries now advise commencing early prophylaxis (15-16).
Current prophylaxis regimens do not completely prevent joint disease (13). In the last few years, more intensive prophylaxis regimens have been explored (17), achieving almost zero joint bleeds. To get the best outcomes with the available bleeding pattern, condition of their musculoskeletal system, level of physical activity and the pharmacokinetic profile of the clotting factor concentrate used (18) (19) (20) (21) (22) .
In order to optimize therapeutic regimens related to outcomes, several studies suggested starting with a once-weekly regimen (23) (24) .
Von Willebrand Disease
Although VWD is more prevalent than haemophilia, less evidence is available on its optimal management, probably due to the lesser number of patients with severe (28) (29) (30) (31) . Antifibrinolytic agents such as tranexamic and epsilon aminocaproic acid, platelet concentrates and combined estrogen-progestogen drugs can be co-administered (32) .
Prevention of bleeding is achieved by prophylaxis, which can be performed in case of surgery or invasive procedures (short-term) or, in the severe forms of VWD, to prevent recurrent bleeding episodes (long-term prophylaxis).
Short-term prophylaxis for surgery
The choice of the best treatment regimen before surgery in patients with VWD depends on type of VWD, type of surgery, baseline VWF and FVIII levels, response to DDAVP and its potential side-effects. Factor VIII levels must be maintained above the baseline levels for a prolonged period of time, as in major surgery.
In VWD patients in whom DDAVP is not appropriate due to inadequate response or contraindication, and in patients undergoing major surgery, treatment with virallyinactivated plasma-derived concentrate is recommended (30, 39) . Table 2 shows the VWF/FVIII products licensed in Europe for the treatment of VWD. Many studies documented the efficacy of VWF/FVIII concentrates as prophylaxis of bleeding in VWD patients undergoing surgery or invasive procedures (40) (41) (42) (43) (44) (45) (46) (47) (48) .
The recent literature shows that the best management of VWD undergoing surgery includes a pharmacokinetic study to tailor the loading and maintenance doses of VWF/FVIII concentrates for each patient (49) . This is particularly important considering the heterogeneous nature of VWD and plasma derived concentrates.
The same studies also underscore that, along with VWF levels, FVIII levels should be monitored daily in the postoperative period in order to prevent exposure to high FVIII levels, which can increase the thrombotic risk. Therefore, primary prophylaxis with low molecular weight heparin at the same dosages and schedules used in the general population, are recommended in VWD patients undergoing major surgery or procedures at high risk of venous thromboembolism (50) . In this regard, there is a growing interest in replacement therapy with VWF concentrates almost devoid of FVIII (Wilfactin®). The same considerations are applicable for long-term secondary prophylaxis, particularly in patients with cardiovascular/thromboembolic risk factors.
Recently recombinant VWF concentrate has been licensed in the USA. Safety and pharmacokinetics (PK) of recombinant von Willebrand factor (rVWF) combined at a fixed ratio with recombinant factor VIII (rFVIII) were recently reported in a prospective phase 1, multicenter, randomized clinical trial. rVWF was well tolerated and no thrombotic events, inhibitors, or serious adverse events were observed (51).
Bleeding phenotype in VWD
Clinically, the leading symptom in VWD is bleeding, chiefly of mucosal origin. In the most severe forms of VWD, especially type 3, joint and muscle bleeding resembling that seen in moderate haemophilia A may also be observed. 
Long-term prophylaxis
Patients with severe forms of VWD may present a severe bleeding phenotype, and in these patients secondary long-term prophylaxis with VWF/FVIII concentrate may represent the optimal therapy rather than on-demand treatment on the occasion of bleeding episodes. However, some differences must be considered between VWD and haemophilic patients regarding treatment. VWD; recurrent bleeding stopped in 31 patients, the monthly bleeding frequency and the bleeding score was significantly reduced compared to the pre-prophylaxis rate but one patient developed inhibitor (71) . Each of these three studies were retrospective and involved a relatively small number of patients.
In 2008 an international study group, the VWD PN was established to study the role of prophylaxis in VWD; 74 centres from around the world participated. The first network-sponsored survey by the centres showed that the use of prophylaxis was rare in type 1 and 2 VWD patients but was most common in type 3 disease.
Prophylaxis was given to prevent joint bleeding (40%), epistaxis/oral bleeding (23%), gastrointestinal bleeding (14%) and menorrhagia (5%) (72) . With the objective of investigating the response to prophylaxis, focusing on specific bleeding type, a recent analysis was conducted combining data from the retrospective and prospective VIP study, and analyzing a cohort of 105 subjects (74) .
The authors concluded that institution of regular replacement therapy has a dramatic effect on bleeding frequency but does not change the proportions of type of bleeds that occur to a great extent. There is variation among patients with regard to response to therapy, both among and within subtypes of VWD. GI bleeding stands out as having a lower response to prophylaxis than other bleeding sites and requiring more frequent prophylactic infusions. It was also noted that when the treatment frequency is escalated for joint bleeding, higher doses were used. Table 3 shows the studies reporting on the use of long-term prophylaxis in VWD.
Although clinical experience with VWD/FVIII prophylaxis has been rated as satisfactory, some uncertainties persist such as the optimal dose of concentrate and the regimen for prophylaxis, due to the wide heterogeneity of the bleeding tendency that impacts heavily on QoL.
CONCLUSION/FUTURE Perspectives
A selected population of VWF with severe bleeding phenotype may benefit from long-term prophylaxis with VWF concentrate. The standardization and validation of B "
bleed (76-78) will likely aid individualizing therapy.
In contrast to haemophilia, pharmacoeconomic analysis to assess the economic impact of treatment of severe VWD, comparing on demand versus prophylactic regimens are still lacking. A recent Italian cost-analysis on long-term prophylaxis in VWD in the Italian context (79) showed (with some limitations due to the single case reports used for the analysis) that long-term prophylaxis with VWF with a low FVIII content is likely to be a cost-effective approach with a favorable impact on the reduction of health care resource consumption and with the improvement in the QoL of the patients. However, more prospective trials are needed to evaluate the cost-Q L -term prophylaxis.
VWF produced by recombinant technology could offer an additional option for the treatment of VWD by eliminating infective risks associated with plasma products. It is now time to seriously consider prophylaxis for severe VWD as a standard of care rather than novelty. 
